Search results for "haloperidol"

showing 10 items of 50 documents

Enhancement in Phospholipase D Activity as a New Proposed Molecular Mechanism of Haloperidol-Induced Neurotoxicity

2020

Membrane phospholipase D (PLD) is associated with numerous neuronal functions, such as axonal growth, synaptogenesis, formation of secretory vesicles, neurodegeneration, and apoptosis. PLD acts mainly on phosphatidylcholine, from which phosphatidic acid (PA) and choline are formed. In turn, PA is a key element of the PLD-dependent secondary messenger system. Changes in PLD activity are associated with the mechanism of action of olanzapine, an atypical antipsychotic. The aim of the present study was to assess the effect of short-term administration of the first-generation antipsychotic drugs haloperidol, chlorpromazine, and fluphenazine on membrane PLD activity in the rat brain. Animals were…

0301 basic medicineFluphenazineolanzapinePhospholipasePharmacologyCatalysishaloperidollcsh:ChemistryInorganic Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineneurotoxicityHaloperidolmedicineAnimalsphospholipase DPhospholipase D activityPhysical and Theoretical ChemistryChlorpromazinechlorpromazinelcsh:QH301-705.5Molecular BiologySpectroscopy030102 biochemistry & molecular biologyPhospholipase DCommunicationOrganic ChemistryGeneral MedicinePhosphatidic acidfluphenazineRatsComputer Science ApplicationsEnzyme Activationenzymes and coenzymes (carbohydrates)lcsh:Biology (General)lcsh:QD1-999chemistryMechanism of actionneuroprotectionlipids (amino acids peptides and proteins)medicine.symptom030217 neurology & neurosurgerymedicine.drugInternational Journal of Molecular Sciences
researchProduct

Haloperidola 5mg/mL šķīduma injekcijām attīrīšanas metodes izstrāde un validācija ar augsti efektīvo šķidruma hromatogrāfiju

2015

Haloperidola 5mg/mL šķīduma injekcijām attīrīšanas metodes izstrāde un validācija ar augsti efektīvo šķidruma hromatogrāfiju. I.Amnuels. Zinātniskie vadītāji: Mg. chem. K.Kuprevičs, Prof., Dr. chem. A.Vīksna. Maģistra darbs, 49 lpp. Satur 22 tabulas, 4 attēlus, astoņus pielikumus un tajā izmantoti 35 literatūras avoti. Darbs uzrakstīts latviešu valodā Darbā veikta Haloperidola attīrīšanas metodes izstrāde un validācija ar AEŠH. Literatūras apskatā apkopota informācija par analīzes metožu validācijas dažiem parametriem, iekārtu attīrīšanas līmeņiem, uztriepju noņemšanas metodiku. Literatūras apskatā ir izmantota literatūra par laika periodu no 1993 līdz 2015 gadam, izmantojot zinātniskus žur…

ATTĪRĪŠANAVALIDĀCIJAHALOPERIDOLSAUGSTI EFEKTĪVĀ ŠĶIDRUMA HROMATOGRĀFIJA (AEŠH)ĶīmijaUZTRIEPE
researchProduct

Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study

2016

Schizophrenia is a severe neuropsychiatric disorder with impairments in social cognition. Several brain regions have been implicated in social cognition, including the nucleus caudatus, prefrontal and temporal cortex, and cerebellum. Oxytocin is a critical modulator of social cognition and the formation and maintenance of social relationships and was shown to improve symptoms and social cognition in schizophrenia patients. However, it is unknown whether the oxytocin receptor is altered in the brain. Therefore, we used qRT-PCR and Ornithine Vasotocin Analog ([125I]OVTA)-based receptor autoradiography to investigate oxytocin receptor expression at both the mRNA and protein level in the left p…

AdultMaleGene ExpressionVasotocinReal-Time Polymerase Chain ReactionLeft nucleusRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHaloperidolAnimalsHumansRNA MessengerClozapineBiological PsychiatryClozapineAgedAged 80 and overTemporal cortexBinding SitesBrainMiddle Agedmedicine.diseaseOxytocin receptor030227 psychiatryPsychiatry and Mental healthchemistryOxytocinReceptors OxytocinSchizophreniaSchizophreniaAutoradiographyHaloperidolFemalePsychologyNeurosciencehormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugSchizophrenia Research
researchProduct

Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables

2012

The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were 174 consecutive subjects included in a first episode programme with no prior treatment with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone in a randomized, open-label, prospective clinical trial. The main outcome variable was the remission criteria developed by the Remission in Schizophrenia Working Group. Clinical variables were included in a logistic regression analysis in order to predict the remission state at 1 year. At 1 year, 31% of patients met criteria for remis…

AdultMaleOlanzapinePediatricsmedicine.medical_specialtymedicine.medical_treatmentLogistic regressionSeverity of Illness IndexTime-to-TreatmentBenzodiazepinesYoung AdultRisk FactorsmedicineHumansLongitudinal StudiesAntipsychoticPsychiatryBiological PsychiatryFirst episodeRisperidoneRemission InductionPrognosisRisperidonemedicine.diseaseClinical trialPsychiatry and Mental healthLogistic ModelsPsychotic DisordersOlanzapineSchizophreniadupSchizophreniaEducational StatusHaloperidolFemaleSchizophrenic PsychologyPsychologyAntipsychotic Agentsmedicine.drugPsychiatry Research
researchProduct

Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Me…

2019

Background Impaired subjective well-being in schizophrenia patients treated with antipsychotics has often been linked inter alia to the antidopaminergic effects of medication. Thus, it is important to capture the association between striatal dopamine D2 receptor occupancy (D2-RO) and global subjective well-being. We examined this association using data from our multicenter, randomized, double-blind Neuroleptic Strategy Study (NeSSy). Methods An innovative double randomization process was used for allocation of patients to the specific treatment groups. Plasma drug concentrations were measured after 6 and 24 weeks of treatment to obtain the estimated D2-RO (eD2-RO) relative to literature val…

AdultMaleOlanzapinemedicine.medical_specialtymedicine.medical_treatmentAripiprazolePersonal SatisfactionMedication Adherencelaw.invention03 medical and health sciencesSex Factors0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHaloperidolHumansPharmacology (medical)AntipsychoticReceptors Dopamine D2business.industryMiddle Agedmedicine.disease3. Good health030227 psychiatryFlupentixolFlupenthixolDopamine D2 Receptor AntagonistsPsychiatry and Mental healthOlanzapineSchizophreniaQuality of LifeSchizophreniaHaloperidolQuetiapineFemaleSchizophrenic PsychologyAripiprazolebusiness030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo

2003

Udgivelsesdato: 2003-Apr The antipsychotic effect of neuroleptics cannot be attributed entirely to acute blockade of postsynaptic D(2)-like dopamine (DA) receptors, but may arise in conjunction with the delayed depolarization block of the presynaptic neurons and reduced DA synthesis capacity. Whereas the phenomenon of depolarization block is well established in animals, it is unknown if a similar phenomenon occurs in humans treated with neuroleptics. We hypothesized that haloperidol treatment should result in decreased DA synthesis capacity. We used 6-[(18)F]fluoro-L-dopa (FDOPA) and positron emission tomography (PET) in conjunction with compartmental modeling to measure the relative activi…

AdultMalePsychosismedicine.medical_specialtyPatientsDopamineDown-RegulationStatistics NonparametricDopamineInternal medicinemedicineHaloperidolHumansPharmacologybusiness.industryPutamenDopamine antagonistBrainDepolarizationHuman brainMiddle Agedmedicine.diseasePsychiatry and Mental healthEndocrinologymedicine.anatomical_structureCerebral cortexAnesthesiaSchizophreniaHaloperidolbusinessTomography Emission-Computedmedicine.drug
researchProduct

Risperidone Versus Haloperidol and Amitriptyline in the Treatment of Patients With a Combined Psychotic and Depressive Syndrome

1998

In a multicenter, double-blind, parallel group trial, the efficacy of risperidone (RIS) was compared with a combination of haloperidol and amitriptyline (HAL/AMI) over 6 weeks in patients with coexisting psychotic and depressive symptoms with either a schizoaffective disorder, depressive type, a major depression with psychotic features, or a nonresidual schizophrenia with major depressive symptoms according to DSM-III-R criteria. A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6.9 mg RIS versus 9 mg HAL combined with 180 mg AMI. Efficacy results for those 98 patients (47 RIS; 51 HAL/AMI) who completed at least 3 weeks of double-blind treatme…

AdultMalemedicine.medical_specialtyAdolescentAmitriptylineSchizoaffective disorderAntidepressive Agents Tricycliclaw.inventionDouble-Blind MethodExtrapyramidal symptomsRandomized controlled triallawInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmitriptylinePsychiatryAgedPsychiatric Status Rating ScalesDepressive DisorderRisperidoneMiddle AgedRisperidonemedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaHaloperidolFemalemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Dose-Related Effects of Amisulpride on Five Dimensions of Psychopathology in Patients With Acute Exacerbation of Schizophrenia

2002

The present analysis investigated symptom-specific dose-response relationships of the atypical antipsychotic amisulpride (AMI) in schizophrenic patients. The effects of different AMI doses on five different symptom dimensions of the Brief Psychiatric Rating Scale (BPRS) were analyzed. Results on global efficacy and safety parameters have been previously published. Four AMI doses (100 mg/day [AMI100], 400 mg/day [AMI400], 800 mg/day [AMI800], 1200 mg/day) were compared with 16 mg haloperidol (HAL16) in a multicenter, double-blind, randomized, parallel-group, 4-week trial. A total of 319 patients with acute exacerbation of schizophrenia (DSM-III-R) were included. AMI100 was compared with the …

AdultMalemedicine.medical_specialtyAdolescentExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmisulpridePsychiatryAntipsychoticPsychiatric Status Rating ScalesDose-Response Relationship DrugDopamine antagonistMiddle AgedPsychiatry and Mental healthTreatment OutcomeSchizophreniaHaloperidolAnxietyFemaleSchizophrenic PsychologyAmisulprideSulpiridemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects

1997

[123I]Iodobenzamide (IBZM) is an iodine-labeled dopamine receptor ligand and can be used to visualize brain D2 receptors in humans with single photon emission computerized tomography (SPECT). The ratio of striatal IBZM uptake to uptake in frontal cortex (ST/FC ratio) represents a semiquantitative measure of D2 receptor binding in the striatum. Our study sample included six patients treated with haloperidol (3.0-8.0 mg/day orally; one patient with an average of 0.9 mg/day intramuscularly), five patients with benperidol (9.0-15.0 mg/day orally) and nine patients treated with clozapine (200.0-600.0 mg/day orally). Typical neuroleptics (TNs) and atypical neuroleptics (ANs) were significantly di…

AdultMalemedicine.medical_specialtyBipolar DisorderPyrrolidinesNeuroscience (miscellaneous)Benperidolchemistry.chemical_compoundIodobenzamideBasal Ganglia DiseasesDopamineInternal medicineDopamine receptor D2medicineHaloperidolHumansRadiology Nuclear Medicine and imagingChlorpromazineClozapineClozapineAgedNeurologic ExaminationPsychiatric Status Rating ScalesTomography Emission-Computed Single-PhotonDepressive Disorder MajorSchizophrenia ParanoidDose-Response Relationship DrugReceptors Dopamine D2business.industryBenperidolBrainMiddle AgedCorpus StriatumFrontal LobePsychiatry and Mental healthEndocrinologychemistryDopamine receptorBenzamidesDopamine AntagonistsHaloperidolFemalebusinessAntipsychotic Agentsmedicine.drugPsychiatry Research: Neuroimaging
researchProduct

Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomog…

2007

The telencephalic dopamine innervations contribute to the modulation of cognitive processing. However, the relationship between cognitive effects of D(2/3)-receptor antagonism and dopamine transmission is not described in healthy subjects. We therefore tested effects of acute haloperidol (5 mg/d over 3 days) on continuous performance task (CPT) performance and 6-[(18)F]-fluoro-l-DOPA (FDOPA) PET parameters. Nine physically and mentally healthy male men performed two FDOPA-PET scans including arterial plasma withdrawal. Over 3 days before the second scan, all subjects were treated with 5 mg/d haloperidol orally. Using our novel steady-state analysis, we calculated the intrinsic rate of the c…

AdultMalemedicine.medical_specialtyCognitive NeuroscienceDopamineKineticsStriatumNeuropsychological TestsCognitionDopamineContinuous performance taskFluorodeoxyglucose F18Predictive Value of TestsInternal medicinemedicineHaloperidolImage Processing Computer-AssistedHumansEffects of sleep deprivation on cognitive performancePsychiatryBrain Chemistrymedicine.diagnostic_testHealthy subjectsReceptors Dopamine D3BrainMiddle AgedDopamine D2 Receptor AntagonistsEndocrinologyNeurologyPositron emission tomographyData Interpretation StatisticalPositron-Emission TomographyDopamine AntagonistsHaloperidolFemaleRadiopharmaceuticalsPsychologyAlgorithmsPsychomotor Performancemedicine.drugNeuroImage
researchProduct